

Q3 2022 Financial Results

Appendix

Alnylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended		Nine Months Ended	
	September 30, 2022	September 30, 2021	September 30, 2022	September 30, 2021
Reconciliation of GAAP to Non-GAAP research and development:				
GAAP Research and development	\$ 245,371	\$ 194,572	\$ 620,976	\$ 563,106
Less: Stock-based compensation expenses	(52,962)	(12,417)	(75,217)	(49,878)
Non-GAAP Research and development	<u>\$ 192,409</u>	<u>\$ 182,155</u>	<u>\$ 545,759</u>	<u>\$ 513,228</u>
Reconciliation of GAAP to Non-GAAP selling, general and administrative:				
GAAP Selling, general and administrative	\$ 235,859	\$ 142,075	\$ 560,314	\$ 434,257
Less: Stock-based compensation expenses	(75,156)	(20,950)	(112,665)	(71,257)
Non-GAAP Selling, general and administrative	<u>\$ 160,703</u>	<u>\$ 121,125</u>	<u>\$ 447,649</u>	<u>\$ 363,000</u>
Reconciliation of GAAP to Non-GAAP operating loss:				
GAAP Operating loss	\$ (258,040)	\$ (181,677)	\$ (596,458)	\$ (514,091)
Add: Stock-based compensation expenses	128,118	33,367	187,882	121,135
Non-GAAP Operating loss	<u>\$ (129,922)</u>	<u>\$ (148,310)</u>	<u>\$ (408,576)</u>	<u>\$ (392,956)</u>

Anylam Pharmaceuticals, Inc.

Reconciliation of Revenue and Growth at Constant Currency

	September 30, 2022	
	Three Months Ended	Nine Months Ended
ONPATTRO net product revenue growth, as reported	20 %	30 %
Add: Impact of foreign currency translation	11	8
ONPATTRO net product revenue growth at constant currency	<u>31 %</u>	<u>38 %</u>
AMVUTTRA net product revenue growth, as reported	N/A	N/A
Add: Impact of foreign currency translation	N/A	N/A
AMVUTTRA net product revenue growth at constant currency	<u>— %</u>	<u>— %</u>
GIVLAARI net product revenue growth, as reported	43 %	45 %
Add: Impact of foreign currency translation	7	5
GIVLAARI net product revenue growth at constant currency	<u>50 %</u>	<u>50 %</u>
OXLUMO net product revenue growth, as reported	10 %	14 %
Add: Impact of foreign currency translation	10	7
OXLUMO net product revenue growth at constant currency	<u>20 %</u>	<u>21 %</u>
Total net product revenue growth, as reported	39 %	36 %
Add: Impact of foreign currency translation	10	8
Total net product revenue growth at constant currency	<u>49 %</u>	<u>44 %</u>